Method for treating individuals having cancer and who are receiving cancer immunotherapy
The methods described herein are for treating infections in individuals having cancer and who are receiving cancer immunotherapy, preferably employing a CRISPR system to selectively kill or reduce the numbers of pathogenic bacteria within the individual and thereafter, administering an immune checkpoint inhibitor thereto. In particular embodiments, the pathogenic bacteria is one of E. coli, Pseudomonas aeruginosa, Klebsiella bacteria, Staphylococcus aureus; Streptoccocus; Salmonella; Shigella; Mycobacterium tuberculosis; Enterococcus; Clostridium; Neisseria gonnorrhoea; Acinetobacter baumannii ; and Campylobacter bacteria and the checkpoint inhibitor is selected from the group consisting of nivolumab, pembrolizumab, pidilizumab, AMP-224, AMP-514, STI-A1110, TSR-042, RG-7446, BMS-936559, MEDI-4736, MSB-0020718C, AUR-012 and STI-A1010. Further embodiments include enhancing the growth of a second bacteria in the individual, such bacteria including Akkermansia, Bacteroides, Bifidobacterium, Enterococcus, Fusobacterium, Coprococcus, LactoBacillus, Propionibacterium, Ruminococcus, Veillonella, Prevotella , and F. prausnitzii . The CRISPR system may include Cas9, Cpf1 and Cas3, and may be delivered using a bacteriophage.
1. A method for treating an individual suffering from an infectious disease and who has cancer, comprising, using a clustered regularly interspaced short palindromic repeats (CRISPR) CRISPR associated protein (Cas), selectively killing or retarding the growth of a pathogenic bacteria within the individual, said pathogenic bacteria selected from the group consisting of Staphylococcus aureus; Pseudomonas aeruginosa; Klebsiella ; Streptoccocus; Salmonella; Shigella; Mycobacterium tuberculosis; Enterococcus; E coli; Clostridium; Neisseria gonorrhoeae; Acinetobacter baumannii ; and Campylobacter , and enhancing the growth of a beneficial bacteria in the individual selected from the group consisting of Akkermansia, Bacteroides, Bifidobacterium, Fusobacterium, Coprococcus, Lactobacillus, Propionibacterium, Ruminococcus, Veillonella, Prevotella , and Streptococcus bacteria; and
administering to the individual an immune checkpoint inhibitor selected from the group consisting of nivolumab, dostarlimab, pembrolizumab, pidilizumab, AMP-224, AMP-514, STI-A1110, RG-7446, BMS-936559, MEDI-4736, MSB-0020718C, AUR-012 and STI-A1010.
2. The method as set forth in claim 1 , wherein the cancer comprises colorectal or bladder cancer.
3. The method as set forth in claim 1 , wherein said CRISPR Cas system comprises Cas3 and is delivered using a bacteriophage.
4. The method as set forth in claim 1 , wherein using the CRISPR-Cas system, said pathogenic bacteria are killed while sparing other commensal bacteria.
5. The method as set forth in claim 1 , wherein the pathogenic bacteria comprises Klebsiella pneumoniae.
6. The method as set forth in claim 1 , wherein the CRISPR-Cas system is used to reduce virulence factors of the pathogenic bacteria.
7. A method for treating an individual suffering from an infectious disease and who has cancer, comprising, using a clustered regularly interspaced short palindromic repeats (CRISPR) CRISPR associated protein (Cas) system or a CRISPR from Prevotella and Francisella 1 (Cpf1), selectively killing pathogenic bacteria within the individual, said pathogenic bacteria comprising at least one of Staphylococcus aureus; Pseudomonas aeruginosa; Klebsiella ; Streptoccocus; Salmonella; Shigella; Mycobacterium tuberculosis; Enterococcus; E coli; Clostridium; Neisseria gonorrhoeae; Acinetobacter baumannii; Enterobacter aerogenes ; and Campylobacter , and administering to the individual an immune checkpoint inhibitor that specifically binds to an immune checkpoint protein selected from the group consisting of CTLA4, PD-1, PD-L1, PD-L2, A2AR, B7-H3, B7-H4, BTLA, KIR, LAG3, TIM-3 and VISTA; and wherein the immune checkpoint inhibitor is selected from the group consisting of nivolumab, pembrolizumab, pidilizumab, AMP-224, AMP-514, STI-A1110, TSR-042, RG-7446, BMS-936559, MEDI-4736, MSB-0020718C, AUR-012 and STI-A1010.
8. The method as set forth in claim 7 , wherein the infection is selected from the group consisting of a skin infection, urinary infection and vaginal infection.
9. The method as set forth in claim 7 , wherein the CRISPR-Cpf1 system is used to cut a gene expressed by the pathogenic bacteria and the pathogenic bacteria comprises one of E. coli, Enterococcus faecalis, Enterococcus faccium and Enterococcus durans.
10. The method as set forth in claim 7 , wherein the CRISPR-Cas or Cpf1 system is used to insert genes that have controllable elements such that the pathogenic bacteria cells are killed by triggering the expression of said inserted genes.
11. The method as set forth in claim 7 , wherein the CRISPR-Cas system or Cpf1 system is delivered by a bacteriophage.
12. The method as set forth in claim 7 , wherein said pathogenic bacteria comprises at least one of Enterobacter aerogenes, Acinetobacter baumannii , and Klebsiella pneumoniae.
13. The method of claim 7 , further comprising enhancing the growth of a beneficial bacteria in the individual selected from the group consisting of, Bacteroides, Fusobacterium, Coprococcus, Lactobacillus, Propionibacterium, Ruminococcus, Veillonella, Prevotella, Streptococcus bacteria, Faecalibacterium prausnitzii, Bifidobacterium, Lachnospira, Akkermansia muciniphila and Rothia.
14. The method as set forth in claim 7 , wherein the CRISPR-Cas or Cpf1 system is used to cut a gene expressed by the pathogenic bacteria.
15. The method as set forth in claim 7 , wherein CRISPR-Cas or Cpf1 is used to insert antibacterial sensitivity into the genome of said pathogenic bacteria such that the pathogenic bacteria can selectively be killed.
16. The method as set forth in claim 7 , wherein CRISPR-Cas or Cpf1 is used to facilitate RNA-guided site-specific DNA cleavage to kill the pathogenic bacteria.
17. The method as set forth in claim 7 , wherein using CRISPR-Cas systems, said pathogenic bacteria are killed while sparing other commensal bacteria, said commensal bacteria selected from the group consisting of Faecalibacterium prausnitzii, Bifidobacterium, Lachnospira, Veillonella, Coprococcus, Akkermansia muciniphila and Rothia.
18. The method as set forth in claim 7 , wherein the cancer comprises colorectal or bladder cancer.
19. A method for treating an individual suffering from an infectious disease and cancer, comprising, using a clustered regularly interspaced short palindromic repeats (CRISPR) CRISPR associated protein (Cas) system from Prevotella and Francisella 1 (Cpf1), selectively killing a pathogenic bacteria within the individual, said pathogenic bacteria selected from the group consisting of: Staphylococcus aureus; Pseudomonas aeruginosa; Klebsiella ; Streptoccocus; Salmonella; Shigella; Mycobacterium tuberculosis; Enterococcus; E coli; Clostridium; Neisseria gonorrhoeae; Acinetobacter baumannii ; and Campylobacter , wherein the CRISPR-Cpf1 system is used to cut a gene expressed by the pathogenic bacteria; wherein the CRISPR-Cpf1 system is used to facilitate RNA-guided site-specific DNA cleavage to kill the pathogenic bacteria; wherein using the CRISPR-Cpf1 system said pathogenic bacteria are killed while sparing other commensal bacteria; and wherein the CRISPR-Cpf1 system is delivered to the pathogenic bacteria using a bacteriophage.
20. The method as set forth in claim 19 , wherein the CRISPR-Cpf1 system is used to insert genes that have controllable elements such that the pathogenic bacteria cells are killed by triggering the expression of said inserted genes.